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Abstract
We investigated the impact of helminths and malaria infection on Kaposi’s sarcoma associ-
ated herpesvirus (KSHV) seropositivity, using samples and data collected from a cluster-
randomised trial of intensive versus standard anthelminthic treatment. The trial was carried
out in 2012 to 2016 among fishing communities on Lake Victoria islands in Uganda. Plasma
samples from 2881 participants from two household surveys, the baseline (1310 partici-
pants) and the final (1571 participants) surveys were tested for KSHV IgG antibody
responses to K8.1 and ORF73 recombinant proteins using ELISA. The baseline survey was
carried out before the trial intervention while the final survey was carried out after three
years of the trial intervention. Additionally, a subset sample of 372 participants from the final
survey was tested for IgE, IgG and IgG4 antibody concentrations to S. mansoni adults worm
antigen (SWA) and S. mansoni egg antigen (SEA) using ELISA. Infection by helminths (S.
mansoni, N. americanus, T. trichiura and S. stercoralis) was diagnosed using real-time
PCR, urine circulating cathodic antigen (CCA) and stool microscopy (Kato-Katz method)
while malaria infection was diagnosed using microscopy. We analysed the relationship
between helminth and malaria infections and KSHV seropositivity using regression model-
ling, allowing for survey design.
At baseline, 56% of the participants were male while 48% of the participants were male in
the final survey. The most prevalent helminth infection was S. mansoni (at baseline 52%
and 34% in the final survey by microscopy, 86% by CCA and 50% by PCR in the final sur-
vey). KSHV seropositivity was 66% (baseline) and 56% (final survey) among those 1–12
years and >80% in those 13+ years in both surveys; malaria parasitaemia prevalence was
7% (baseline) and 4% (final survey). At baseline, individuals infected with S. mansoni
(detected by microscopy) were more likely to be KSHV seropositive (aOR = 1.86 (1.16,
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2.99) p = 0.012) and had higher anti-K8.1 antibody levels (acoefficient = 0.03 (0.01, 0.06) p
= 0.02). In the final survey, S. mansoni (by microscopy, adjusted Odds Ratio (aOR = 1.43
(1.04–1.95), p = 0.028) and malaria parasitaemia (aOR = 3.49 (1.08–11.28), p = 0.038)
were positively associated with KSHV seropositivity. Additionally, KSHV seropositive partici-
pants had higher S. mansoni-specific IgE and IgG antibody concentrations in plasma. Fur-
thermore, HIV infected individuals on cART were less likely to be KSHV seropositive
compared to HIV negative individuals (aOR = 0.46 (0.30, 0.71) p = 0.002).
Schistosoma species skew the immune response towards Th2 and regulatory
responses, which could impact on KSHV reactivation if co-infected with both organisms.
Author summary
Kaposi’s sarcoma associated herpesvirus (KSHV), the causative agent of Kaposi’s sarcoma
cancer, varies geographically. KSHV infections are highest in sub-Saharan Africa, with
Uganda having the highest prevalence reported to date. Infection with KSHV is lifelong
with an intermittent revival of the virus, leading to viral spread. In this study, we show
that infection with Schistosoma mansoni and malaria parasites is associated with being
infected or exposed to KSHV. These parasite infections interfere with the proper function-
ing of the immune system to control viral infections. Although not shown in the current
study, these parasite infections might lead to reactivation of KSHV in infected people
increasing the likelihood of having detectable KSHV antibodies. Consequently, this viral
reactivation may increase the spread of KSHV in sub-Saharan Africa.
Introduction
The prevalence of Kaposi’s sarcoma associated herpesvirus (KSHV), also known as human
herpesvirus 8 (HHV8), varies geographically, unlike that of other herpesviruses which are
ubiquitous [1–3]. Uganda has a high prevalence of KSHV [4, 5] and a high incidence of Kapo-
si’s sarcoma (KS) [6, 7]. The incidence of KS rises dramatically among immunocompromised
individuals [8–10]; immunosuppression has been implicated in the reactivation of KSHV and
the progression of KS [9, 11].
Co-infection with helminths has been shown to modulate immune responses to other infec-
tions and vaccines [12–14]. Chronic infection with Schistosoma is characterised by the produc-
tion of IL4, IL5 and IL13 cytokines, typical of a T helper (Th) type 2 response and IL10, a
regulatory cytokine [15, 16]. The skewed immune response to a Th2 and regulatory response
may impair the T helper (Th) 1 response, vital for control of viral infections [17–19]. The
impact of Schistosoma co-infection on herpesviruses and other viruses has been demonstrated
in animal models, where Schistosoma mansoni infection led to IL4-mediated reactivation of
murine herpesvirus 68 and M2 macrophage polarization [17, 18].
Our group has documented associations between KSHV antibodies and parasite infections
including P. falciparum and helminths (hookworm and Mansonella perstans) in rural [4] and
peri-urban [20–22] populations in Uganda. The Lake Victoria island communities in East
Africa are characterised by poor sanitation and a high prevalence of infectious diseases, includ-
ing schistosomiasis [23–26]. No study to date has documented the burden of KSHV or KS in
these unique communities. This study aimed to determine the seropositivity of KSHV in the
Kaposi’s sarcoma herpesvirus and parasite infection
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Lake Victoria island communities of Koome sub-county, Uganda and the association between
KSHV seropositivity and parasite co-infections.
Methods
Study population, participant selection and ethical approval
This cross-sectional study used samples from an open cluster-randomised trial of intensive ver-
sus standard anthelminthic treatment, the Lake Victoria Island Intervention Study on Worms
and Allergy-related diseases (LaVIISWA) (ISRCTN47196031) [27]. The study was carried out in
the Lake Victoria island communities of Koome sub-county, Mukono district, Uganda between
September 2012 and August 2016. Twenty-six island villages were included in the trial. These 26
villages were randomised to receive either standard or intensive anthelminthic treatment, with
13 villages in each trial arm. Residents of villages in the standard arm were offered a single dose
of albendazole (400mg) twice yearly and a single dose of praziquantel (40mg/Kg) annually. Resi-
dents of villages in the intensive arm received a triple dose of albendazole (400mgX3) and a sin-
gle dose of praziquantel (40mg/Kg), given four times yearly. Details of the trial are published
elsewhere [27, 28]. Two major separate surveys were carried out, one at baseline before the trial
intervention (baseline survey) and the second after three years of the trial intervention (final sur-
vey). At baseline, a household survey was conducted where 32 to 45 households per village were
selected at random to participate. After three years of the intervention, the final household sur-
vey was conducted, which involved selecting a random sample of 70 households per village. All
residents aged one year and above of selected households were invited to participate. Separate
random households were selected for each survey, without individual participant follow-up.
Data on socio-demographic characteristics were collected, clinical examinations were per-
formed, and blood and stool samples were taken. A total of 1310 (baseline survey) and 1571
(final survey) plasma samples were selected randomly for KSHV antibody testing. Ethical
approvals were obtained from the Uganda Virus Research Institute Research and Ethics Com-
mittee (reference number: GC/127/17/04/317), the Uganda National Council for Science and
Technology (reference number: HS1183) and the London School of Hygiene & Tropical Medi-
cine Research and Ethics committee (reference number: 9917–9). Written informed consent
was obtained from all adults aged 18 years and above. Children below 18 years were consented
into the study by their parents or guardians; we also sought, in addition to parental consent,
written assent from children aged between 8–17 years.
Serology
IgG antibodies to K8.1 and ORF73 recombinat proteins were measured using ELISA to deter-
mine KSHV seropositivity, as previously described [29]. Each plate contained three negative
and positive controls. The negative controls were used to determine the cut-off value. Seropos-
itivity was defined as reactivity to either K8.1 or ORF73 antigens or both. This assay has been
shown to be specific and sentitive to KSHV infection [29]. IgE, IgG (all subclasses) and IgG4
antibody concentrations to Schistosoma mansoni Egg Antigen (SEA) and Schistosoma mansoni
adult Worm Antigen (SWA) were measured using ELISA. Antigen concentrations of 8 μg/mL
(SWA) and 2.4 μg/mL (SEA) plus sample dilutions of 1/20 (IgE), 1/200 (IgG4) and 1/3000
(IgG) were used, as previously reported [14, 30, 31].
Diagnostic testing and socio-demographic data collection
Duplicate slides were made from each stool sample and analysed independently by two techni-
cians for helminth infection and intensity using the Kato-Katz (KK) method [32]. The
Kaposi’s sarcoma herpesvirus and parasite infection
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following thresholds were used for classification of S. mansoni infection intensities: 1–99 eggs
per gram of stool as light intensity, 100–399 eggs per gram of stool as moderate intensity and
greater than 400 eggs per gram of stool as heavy intensity. An aliquot of the stool was stored in
70% ethanol and later used to detect helminths by real-time PCR. The multiplex real-time
PCR assay was used to detect Necator americanus, Strongyloides stercoralis and Schistosoma
mansoni as previously described [33, 34]. S. mansoni antigens were also tested in urine using
the Circulating Cathodic Antigen (CCA) kits (Rapid Medical Diagnostics, Pretoria, South
Africa) [27]. Mansonella perstans infection was detected using the modified Knott’s method
[35] and thick blood films were made for malaria parasitaemia detection using microscopy.
Questionnaires were administered for demographic data collection while HIV infection status
was determined using rapid HIV diagnostic kits following the Uganda national HIV testing
algorithm.
Statistical analysis
Statistical analysis was carried out using STATA version 13 (StataCorp, College Station, Texas
USA). The survey study design of the main trial was non self-weighting (because the number
of households selected from each village were not dependant on village size, therefore house-
holds from smaller villages were more likely to be included in the survey than households
from larger villages). To allow for this non self-weighting design and to ensure that our analy-
ses are representative of the study area, we therefore took into account clustering within vil-
lages and applied village-level weights to allow for the different village sizes for all
observational analyses [36]. Logistic regression (allowing for the survey design) was used to
determine associations between risk factors and KSHV seropositivity. Linear regression
(allowing for the survey design) was used to determine associations between risk factors and
KSHV antibody levels. Although KSHV antibody levels did not attain normal frequency distri-
butions, they were log10 transformed prior to linear regression modelling. For assessing the
effect of intensive versus standard treatment, the analysis was done at the cluster level. The
proportion of KSHV seropositive participants was calculated for each village, and the mean of
these taken for the two trial arms. The risk ratio (RR) was then calculated by dividing the mean
KSHV prevalence in the intensive arm by that in the standard arm, and a Taylor approxima-
tion was used to calculate a 95% confidence interval for this RR. The p-value was generated
from a t-test comparing the village-level prevalences between the two arms. A similar approach
was used to assess the effect of intensive versus standard treatment on KSHV antibody levels.
A p-value of less than 5% was considered statistically significant. Multivariable models
included age (grouped), sex, HIV status, S. mansoni, hookworm and malaria parasite infection.
Participants not tested for HIV were also included in the analyses.
Results
Participants characteristics
Baseline and final survey results were analysed separately. The median age at baseline was 25
with an interquartile range (IQR) of 3 to 33 years. In the final survey, the median age was 24
years with an interquartile range (IQR) of 9 to 33 years. The overall proportion of males was
56% at baseline and 48% in the final survey. Details of the socio-demographic characteristics
of the study population are shown in Table 1. At baseline, the HIV prevalence was 13% overall
and 17% in those aged 13 years and above. In the final survey, around a quarter of participants
(26%), mainly children, were not tested for HIV. There were 201 HIV seropositive individuals
among 1229 tested (17% prevalence), with 103 participants confirmed to be on antiretroviral
treatment (ART). At baseline, the malaria prevalence was 7% overall and 14% in children
Kaposi’s sarcoma herpesvirus and parasite infection
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below 12 years. In the final survey, malaria infection prevalence was lower, at 4% overall, and
8% in children aged 1 to 12 years. Among the helminth infections tested, Schistosoma mansoni
was the most prevalent in both surveys, as expected, due to the close proximity of the study
sites to the waters of Lake Victoria. The prevalence was 86% by CCA, 50% by PCR and 34% by
microscopy in the final survey (Table 1). At baseline, the prevalence was 72% by CCA in a sub-
set of 569 participants and 52% by microscopy in 1137 participants. Hookworm prevalence
was 7% by microscopy and 26% by PCR at baseline while in the final survey, it was 2% by
Table 1. Characteristics of the study population.
Factor Baseline survey Final survey
n = 1310 n = 1571
Age, median and inter quartile range 25 (3–33) 24 (9–33)
Age group, years
1–12 29% (362/1308) 31% (492/1571)
13–30 40% (546/1308) 39% (596/1571)
31–44 24% (319/1308) 22% (353/1571)
above 44 7% (130/1308) 9% (130/1571)
Sex (males) 56% (744/1310) 48% (801/1571)
HIV prevalence
Overall 13% (145/1150) 17% (201/1229)
Participants aged 1–12 years 0.04% (1/288) 2% (6/270)
Participants aged 13 and above 17% (144/862) 21% (195/959)
ART status
(+) treated 57% (103/201)
(+) untreated 6% (13/201)
(+) no treatment status 37% (85/201)
Malaria infection
Overall 7% (92/1307) 4% (60/1554)
Children (1–12 years) 14% (51/361) 8% (34/491)
Schistosoma mansoni prevalence
Microscopy (KK) 52% (606/1137) 34% (440/1355)
PCR 50% (673/1353)
CCA 72% (414/569) 86% (1225/1430)
Schistosoma mansoni intensity KK
Uninfected 48% (531/1137) 66% (915/1355)
Light infection 20% (238/1137) 16% (216/1355)
Moderate 15% (183/1137) 10% (119/1355)
Heavy 16% (185/1137) 8% (105/1355)
Necator americanus prevalence PCR 26% (295/1136) 8% (120/1353)
Hookworm prevalence KK 7% (82/1137) 2% (30/1355)
Strongyloides stercoralis prevalence PCR 14% (176/1136) 6% (98/1353)
Trichuris trichiura prevalence KK 11% (148/1137) 9% (135/1355)
Ascaris lumbricoides prevalence KK 0.1% (15/1137) 0.04% (8/1355)
Mansonella perstans prevalence 3% (37/1296) 0.9% (14/1567)
Proportions were weighted to allow for the survey design and thus not calculated directly from the numerators and
denominators presented in the table. Helminths infection status and were determined from a single stool sample
using Kato-Katz (KK) method or PCR (polymerase chain reaction) method or both. Rapid tests were used for HIV
screening and microscopy was used for malaria diagnosis.
https://doi.org/10.1371/journal.pntd.0007776.t001
Kaposi’s sarcoma herpesvirus and parasite infection
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microscopy and 8% by PCR. The prevalence of other helminths at baseline was 14% for Stron-
gyloides stercoralis (using PCR), 11% for Trichuris trichiura (using KK), 0.1% for Ascaris lum-
bricoides (using KK) and 3% for Mansonella perstans (Table 1). While in the final survey, the
prevalence of other helminths was 6% for Strongyloides stercoralis (using PCR), 9% for Tri-
churis trichiura (using KK), 0.04% for Ascaris lumbricoides (using KK) and 0.9% for Manso-
nella perstans (Table 1). At baseline, 20% of the S.monsoni infected individuals had light
intensity infections, 15% moderate and 16% heavy infections. On the other hand, the majority
of the infected individuals in the final survey had light to moderate helminth infections; 8%
had a heavy S. mansoni infection based on microscopy (Table 1).
KSHV seropositivity
Overall KSHV seropositivity was 84% at baseline and 75% in the final survey. At baseline, the
prevalence increased from 66% at 1–12 years to 93% in 31–44 years and 90% in 45-74-year-
olds (Fig 1). In the final survey, the prevalence increased steeply with age (overall p<0.0001),
rising from 56% in the 1-12-year age group to 84% in the 13-30-year age group, and plateaued
thereafter (Fig 2).
Associations between KSHV seropositivity and risk factors
We investigated associations of KSHV seropositivity with parasite infections and other factors
at baseline and in the final survey. Overall, KSHV prevalence was higher in males compared to
females (adjusted Odds Ratio (aOR) = 1.72 (1.29, 2.30), p = 0.001) in the final survey (Table 2).
HIV seropositive individuals on ART were less likely to be KSHV seropositive compared to
HIV seronegative individuals in the final survey (Table 2).
Individuals infected with malaria parasites (aOR = 3.49 (1.08, 11.28), p = 0.038) were more
likely to be KSHV seropositive in the final survey (Table 2). Although in the final survey, hook-
worm infection was positively associated with KSHV seropositivity in the unadjusted analysis
(OR = 2.15 (1.18, 3.94), p = 0.015), this association was lost after adjusting for age group, sex,
HIV serostatus, S. mansoni infection status and malaria infection status (Table 2). Helminth
Fig 1. KSHV seropositivity and 95% confidence intervals (CI) across ages 1 to 74 years in the baseline survey.
KSHV Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected using
ELISA. Seropositivity and 95% CI were obtained in STATA, allowing for the survey design.
https://doi.org/10.1371/journal.pntd.0007776.g001
Kaposi’s sarcoma herpesvirus and parasite infection
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infections including Trichuris trichiura and Strongyloides stercoralis showed no association
with KSHV seropositivity both at baseline and in the final survey (Table 3 & Table 2). Other
helminth infections such as Ascaris lumbricoides and Mansonella perstans were not analysed
using regression modelling due to the small numbers of infected participants.
Individuals who were microscopy positive for S. mansoni at baseline (aOR = 1.86 (1.16,
2.99) p = 0.012 (Table 3) and in the final survey (aOR = 1.43 (1.04, 1.95), p = 0.028) (Table 2)
were more likely to be KSHV seropositive. KSHV seropositivity increased with increasing S.
mansoni infection intensity at baseline (p for trend = 0.013) (Table 4). In the final survey, the
seropositivity of KSHV among individuals heavily infected with S. mansoni was 82% compared
to 80% among lightly or moderately infected individuals, and 73% among uninfected individu-
als, although evidence for an increasing prevalence with increasing intensity was borderline
after adjusting for possible confounders (P value for trend = 0.068) (Table 5). We did not
observe significant associations between S. mansoni detected by CCA or PCR and KSHV sero-
positivity (S1 Text and S2 Text). There was no effect of intensive versus standard anthel-
minthic treatment on either KSHV seropositivity or antibody levels (Table 6).
Association between KSHV antibody levels and microscopy status of S.
mansoni infection
We further investigated the association between S. mansoni infection and infection intensity
detected by microscopy and KSHV IgG antibody levels to K8. 1 and ORF73 separately. At
baseline, microscopy positive individuals for S. mansoni had higher antibodies to K8.1 com-
pared to microscopy negative individuals (adjusted linear regression coefficient = 0.03 (0.01,
0.05) p = 0.02). Furthermore, this association increased with increasing infection intensity (p
value for trend = 0.005; S3 Text). Although antibody levels to ORF73 were not associated with
S. mansoni infection at baseline, there was an association between ORF73 antibodies and S.
mansoni infection intensity (p-value for trend = 0.026). Antibody levels to both K8.1 and
ORF73 were neither associated with S. mansoni infection nor with S. mansoni infection inten-
sity in the final survey (S3 Text).
Fig 2. KSHV seropositivity and 95% confidence intervals (CI) across ages 1 to 72 years in the final survey. KSHV
Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected using ELISA.
Seropositivity and 95% CI were obtained in STATA, allowing for the survey design.
https://doi.org/10.1371/journal.pntd.0007776.g002
Kaposi’s sarcoma herpesvirus and parasite infection
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Associations between KSHV seropositivity and Schistosoma mansoni
antibody concentrations
IgE (n = 364), IgG (n = 372) and IgG4 (n = 370) antibody concentrations against S. mansoni
egg and adult worm antigens were measured from the final survey in a subset of individuals
with sufficient plasma for the analysis. Participants whose samples were used for this analysis
were on average older than participants whose samples were not used; other participant char-
acteristics were comparable (S4 Text). After adjusting for age group, sex and HIV status,
increased levels of IgE to SWA (aOR = 55.03 (3.14, 963.65), p = 0.008) and SEA (aOR = 8.20
Table 2. Association between KSHV seropositivity and risk factors in the final survey.
Factor KSHV seropositivity Crude ORa (95% CIb) P value Adjustedc OR (95% CI) P value
Age group (years)
1–12 56% (289/492) 1 1
13–30 84% (511/596) 4.35 (2.80,6.74) 4.84 (2.92, 8.02)
31–44 81% (294/353) 3.44 (2.28, 5.19) 4.13 (2.40, 7.10)
45–72 89% (113/130) 6.65 (3.00,14.77) <0.0001 7.74 (3.47, 17.27) <0.0001
Sex
Female 71% (561/770) 1 1
Male 80% (646/801) 1.68 (1.26, 2.25) 0.001 1.72 (1.29, 2.30) 0.001
HIV status
Negative 79% (813/1028) 1 1
(+) treated 70% (71/103) 0.64 (0.47, 0.87) 0.46 (0.30, 0.71)
(+) untreated 76% (10/13) 0.88 (0.22, 3.50) 0.55 (0.14, 2.16)
(+) no treatment status 85% (73/85) 1.60 (0.82, 3.11) 1.22 (0.57, 2.26)
Not tested 67% (240/342) 0.55 (0.31, 1.00) 0.002 1.05 (0.56, 1.95) 0.002
S. mansoni
Uninfected 73% (676/915) 1 1
Infected 80% (359/440) 1.55 (1.13, 2.11) 0.008 1.43 (1.04, 1.95) 0.028
N. americanus
Uninfected 74% (927/1233) 1 1
Infected 86% (106/120) 2.15 (1.18, 3.94) 0.015 1.55 (0.86, 2.80) 0.136
T. trichiura
Uninfected 75% (924/1220) 1 1
Infected 79% (111/135) 1.25 (0.66, 2.39) 0.480 1.60 (0.83, 3.08) 0.150
S. stercoralis
Uninfected 74% (949/1255) 1 1
Infected 85% (84/98) 1.82 (0.72, 4.62) 0.198 1.03 (0.41, 2.61) 0.947
Malaria
Negative 75% (1142/1494) 1 1
Positive 84% (50/60) 1.76 (0.81, 3.82) 0.144 3.49 (1.08, 11.28) 0.038
Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected using ELISA. Rapid tests were used to determine HIV status.
Statistical analysis was performed using logistic regression, allowing for the survey design. Schistosoma mansoni and Trichuris trichiura infections were determined from
a single stool sample using the Kato-Katz method. Necator americanus and Strongyloides stercoralis infections determined using PCR (polymerase chain reaction)
method.
aOR: odds ratios.
bCI: Confidence Intervals.
c adjusted for age, sex, HIV status, S. mansoni, N. americanus and malaria parasitaemia. Proportions were weighted to allow for the survey design and thus not
calculated directly from the numerators and denominators presented in the table.
https://doi.org/10.1371/journal.pntd.0007776.t002
Kaposi’s sarcoma herpesvirus and parasite infection
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(1.53, 44.05), p = 0.016) as well as IgG to SEA (aOR = 2.57 (1.17, 5.68), p = 0.02) were associ-
ated with an increased risk of being KSHV seropositive (Table 7).
Discussion
KSHV prevalence can vary, even between geographically proximate areas [3]. We have previ-
ously reported a high KSHV seroprevalence of>95% in adults in the General Population
Cohort in rural southwestern Uganda [5], and a prevalence of 61% amongst mothers in a peri-
urban cohort [37]. This current study shows a high seropositivity of KSHV (>80% in 13
+-year-olds) amongst Lake Victoria island communities with seropositive participants as
young as one year. Additionally, we show that males were more likely to be KSHV seropositive
Table 3. Association between KSHV seropositivity and risk factors at baseline.
Factor KSHV seropositivity Crude ORa (95% CIb) P value Adjustedc OR (95% CI) P value
Age group (years)
1–12 66% (236/362) 1 1
13–30 90% (490/546) 4.65 (2.88,7.52) 5.14 (2.92, 9.05)
31–44 93% (290/319) 6.50 (3.16, 13.36) 7.59 (3.31, 17.40)
45–74 90% (74/81) 4.21 (1.41,12.57) <0.0001 6.29 (2.54, 15.58) <0.0001
Sex
Female 81% (450/566) 1 1
Male 86% (641/744) 1.41 (1.03, 1.94) 0.035 1.01 (0.63, 1.59) 0.980
HIV status
Negative 84% (846/1005) 1 1
Positive 89% (126/145) 0.65 (0.79, 3.45) 0.170 0.72 (0.36, 1.47) 0.357
S. mansoni
Uninfected 77% (410/531) 1 1
Infected 89% (533/606) 2.25 (1.45, 3.50) 0.001 1.86 (1.16, 2.99) 0.012
N. americanus
Uninfected 82% (684/841) 1 1
Infected 86% (258/295) 1.32 (0.92, 1.90) 0.125 1.21 (0.68, 2.15) 0.499
T. trichiura
Uninfected 83% (816/989) 1
Infected 86% (127/148) 1.28 (0.62, 2.67) 0.491
S. stercoralis
Uninfected 82% (786/960) 1 1
Infected 89% (156/176) 1.77 (1.08, 2.89) 0.025 0.92 (0.59, 1.44) 0.708
Malaria
Negative 84% (1016/1215) 1 1
Positive 80% (72/92) 1.80 (0.51, 1.25) 0.310 1.27 (0.69, 2.33) 0.428
Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected using ELISA. Rapid tests were used to determine HIV status.
Statistical analysis was performed using logistic regression, allowing for the survey design. Schistosoma mansoni and Trichuris trichiura infections were determined from
a single stool sample using the Kato-Katz method. Necator americanus and Strongyloides stercoralis infections determined using PCR (polymerase chain reaction)
method.
aOR: odds ratios.
bCI: Confidence Intervals.
c adjusted for age, sex, HIV status, S. mansoni, N. americanus and malaria parasitaemia. Proportions were weighted to allow for the survey design and thus not
calculated directly from the numerators and denominators presented in the table.
https://doi.org/10.1371/journal.pntd.0007776.t003
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compared to females. These findings are similar to those documented in other studies carried
out in sub-Saharan Africa [4, 5, 38].
The HIV prevalence in the studied communities was high (17%). We observed a lower risk
of being KSHV seropositive among individuals treated for HIV compared to HIV negative
individuals. Since our study was cross-sectional and given the fact that there was missing HIV
data, this finding should be treated with caution. However, ART has been shown to lead to
tumour regression among AIDS-KS patients [39–41]. Additionally, others have shown a
decline in KSHV viral load following HAART initiation [42–44], perhaps suggesting a direct
effect of ART on KSHV replication.
The high untreated HIV prevalence, coupled with other factors including parasite infec-
tions, may contribute to the high prevalence of KSHV in this area. The burden of S. mansoni
in these island communities is very high. We showed that being infected with S. mansoni,
detected by microscopy, was associated with an increased risk of being KSHV seropositive.
Others have reported no association between S. mansoni and KSHV infections, possibly due to
the low prevalence of KSHV or low infection intensity of S. mansoni in the study areas [45,
46]. In vitro reactivation of the model gammaherpesvirus MHV68 by S. mansoni was demon-
strated by Reese et al., mediated through IL4 production [18]. Our human data are consistent
with this model, as we observed an association with S. mansoni and KSHV seropositivity. Fur-
thermore, at baseline (before antihelminthic treatment), anti-K8.1 antibody levels were higher
in S. mansoni infected individuals compared to uninfected individuals, and S. mansoni infec-
tion intensity was associated with higher antibody levels to K8.1 and ORF73. These
Table 4. Associations between KSHV seropositivity and S. mansoni infection intensity at baseline.
Risk factor KSHV seropositivity Univariate Age, sex, HIV, N. americanus and malaria
adjusted
OR (95% CI) P value OR (95% CI) P value
S. mansoni intensity
Uninfected 77% (410/531) 1 1
Light 87% (203/238) 1.91 (0.93, 3.92) 1.56 (0.79, 3.08)
Moderate 91% (163/183) 3.00 (1.42, 6.37) 2.76 (1.17, 6.52)
Heavy 88% (167/185) 2.20 (1.27, 3.81) <0.0001 trend 1.66 (0.84, 3.26) 0.013 trend
KSHV Seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV antibodies detected using ELISA. OR: odds ratios. Schistosoma mansoni was
determined from a single stool sample using the Kato-Katz method. Statistical analysis was performed using logistic regression, allowing for the survey design.
Proportions were weighted to allow for the survey design and thus not calculated directly from the numerators and denominators presented in the table.
https://doi.org/10.1371/journal.pntd.0007776.t004
Table 5. Associations between KSHV seropositivity and S. mansoni infection intensity in the final survey.
Risk factor KSHV seropositivity Univariate Age, sex, HIV, N. americanus and malaria
adjusted
OR (95% CI) P value OR (95% CI) P value
S. mansoni intensity
Uninfected 73% (676/915) 1 1
Light 80% (173/216) 1.53 (1.14, 2.05) 1.38 (0.98, 1.93)
Moderate 80% (99/119) 1.48 (0.94, 2.33) 1.29 (0.79, 2.11)
Heavy 82% (87/105) 1.68 (0.71, 3.98) 0.049trend 1.74 (0.69, 4.36) 0.068 trend
KSHV Seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV antibodies detected using ELISA. OR: odds ratios. Schistosoma mansoni was
determined from a single stool sample using the Kato-Katz method. Statistical analysis was performed using logistic regression, allowing for the survey design.
Proportions were weighted to allow for the survey design and thus not calculated directly from the numerators and denominators presented in the table.
https://doi.org/10.1371/journal.pntd.0007776.t005
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associations were not observed in the final survey after antihelminthic treatment. Nonetheless,
higher antibody levels to KSHV antigens, and particularly the lytic antigen K8.1, has been asso-
ciated with viral reactivation and KS disease progression [47–50]. Our findings may imply
KSHV reactivation in individuals with a heavy S. mansoni infection, although a major limita-
tion in interpretation is that we are unable to assign causation. An additional limitation is that
we did not measure KSHV viral load in blood due to the unavailability of appropriate samples,
and this would reaffirm the role of S. mansoni infection in KSHV reactivation.
We also showed that increasing IgE and IgG, but not IgG4 antibodies to S. mansoni are
associated with an increased risk of being KSHV seropositive in older individuals. The (Th) 2
immune response to S. mansoni, characterised by IgE, IL4 and IL5 production has been linked
to protection from S mansoni reinfection, while IgG4 production has been linked to suscepti-
bility to reinfection [51]. This protective immunity tends to increase with age and requires
repeated exposure to develop. This would then suggest that S. mansoni, through (Th) 2
immune response upregulation, may reactivate KSHV latently infected cells.
Alternatively, the association between KSHV seropositivity and S. mansoni infection could
be caused by increased inflammation due to new S. mansoni infections, leading to an increase
Table 6. Effect of helminths treatment on KSHV seropositivity and antibody levels.
KSHV seropositivity K8.1 ORF73
KSHV
seropositivity
Crude RRa
(95% CIb)
P
value
Adjusted RR
(95% CI)
P
value
Crude
diffc
(95% CI)
P
value
Adjusted diff
(95% CI)
P
value
Crude diff
(95% CI)
P
value
Adjusted
diff
(95% CI)
P
value
Trial
arm
Standard 78% (550/
710)
1 1 Ref Ref Ref Ref
Intensive 77% (657/
861)
0.99 (0.92,
1.05)
0.690 1.00 (0.93,
1.07)
0.925 0.03
(-0.09,
0.15)
0.644 -0.06 (-0.18,
0.67)
0.352 0.06
(-0.06,
0.15)
0.312 -0.08 (-0.22,
0.06)
0.228
KSHV Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected using ELISA.
aRR: risk ratio.
bCI: confidence Interval.
cDiff: difference. Adjusted for sex, age group and HIV status. Proportions were weighted to allow for the survey design and thus not calculated directly from the
numerators and denominators presented in the table.
https://doi.org/10.1371/journal.pntd.0007776.t006
Table 7. Associations between KSHV seropositivity and Schistosoma mansoni antibody concentrations.
Antibody type Univariate Age, sex and HIV adjusted
OR (95% CI) P value OR (95% CI) P value
IgE to SEA (n = 364) 7.57 (1.54, 37.20) 0.015 8.20 (1.53, 44.05) 0.016
IgE to SWA (n = 364) 83.03 (4.69, 1470.38) 0.004 55.03 (3.14, 963.65) 0.008
IgG to SEA (n = 372) 3.03 (1.19, 7.77) 0.023 2.57 (1.17, 5.68) 0.021
IgG to SWA (n = 372) 6.99 (1.24, 39.49) 0.029 4.22 (0.98, 18.18) 0.053
IgG4 to SEA (n = 370) 1.30 (1.03, 1.62) 0.026 1.23 (0.96, 11.58) 0.097
IgG4 to SWA (n = 370) 1.37 (0.96, 1.97) 0.080 1.18(0.82, 1.71) 0.362
KSHV Seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV and Schistosoma mansoni antibodies
detected using ELISA, measured in ng/mL and converted to μg/mL. OR: odds ratios per unit increase in antibody
level. Statistical analysis was performed using logistic regression, allowing for the survey design. SEA: Schistosoma
mansoni Egg Antigen; SWA: Schistosoma mansoni Worm antigen. Ig: Immunoglobuline
https://doi.org/10.1371/journal.pntd.0007776.t007
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in KSHV antibody levels in individuals already infected with KSHV. However, the association
with anti-K8.1 (a lytic antigen) but not anti-ORF73 (a latent antigen) antibodies with S. man-
soni infection at baseline may imply specific effects of S. mansoni on KSHV reactivation as
opposed to non-specific inflammatory effects. Furthermore, higher anti-Ag85A (a Mycobacte-
ria tuberculosis antigen unrelated to S. mansoni) IgG4, but not IgG, has been reported in S.
mansoni infected individuals compared to S. mansoni uninfected individuals [14]. Taken
together, this might suggest a specific effect of S. mansoni on immunity to other unrelated
chronic infections.
The association between S. mansoni and KSHV seropositivity was only observed if S. man-
soni was detected using microscopy (KK) but not PCR or CCA, in this study. Microscopic
examination of faecal samples is the WHO recommended diagnostic test for S. mansoni [52,
53], and has a documented specificity of 100%, although varying sensitivity (depending on
infection intensity and studied population) has been observed [53, 54]. Detection of S. mansoni
by CCA may be influenced by cross-reactivity, leading to false positives, and may explain the
larger numbers diagnosed by this method in our study [53, 54]. The PCR technique has been
shown to be sensitive and specific for detecting S. mansoni [52–54]. The ability of the PCR
technique to detect low-intensity S. mansoni infection, as well as the reduced infection inten-
sity in the final survey due to the three years antihelminthic treatment, may have obscured the
effect that S. mansoni has on KSHV antibody levels. Heavy S. mansoni infections might have a
larger effect which could easily be observed with the current sample size. Furthermore, a light
infection intensity could have effects on KSHV incident cases, as opposed to prevalent cases.
Because of the observational study design, incident cases were not specifically detected, and
our study likely picked up prevalent cases.
We did not see any effect of intensive versus standard anthelminthic treatment on KSHV
seropositivity. This was not surprisingly as such an intervention would likely affect incident
KSHV infections, rather than prevalent KSHV infections and antibody titres against KSHV
would be unlikely to change over the short follow-up period. Migration rates in these Island
communities were very high. Therefore very few people were tested both at baseline and in the
final survey. Consequently, the majority of the participants analysed in the final survey might
have been new immigrants. The original trial intended to obtain community/population-wide
effects as opposed to individual participant effects.
We also found malaria parasitemia to be associated with KSHV seropositivity, consistent
with our previous findings [4, 21], and these data reinforce the need to investigate the mecha-
nism through which malaria infection impacts on KSHV and its subsequent role in KSHV
transmission. Infection with Plasmodium falciparum, the main cause of malaria disease in
Africa, induces inflammation which is normally regulated through induction of regulatory T
cells and production of IL10 and TGF-β. Increased IL10 levels, a cytokine mainly produced by
regulatory cells, has been reported in disseminated KS [55]. Plasmodia have also been shown
to cause macrophage and dendritic cell dysfunction [56]. The immunosuppression caused by
P. falciparum infection has also been shown to lead to the reactivation of some herpesviruses
such as EBV, HSV-1 and VZV [57–61]. We therefore hypothesize that the immune dysregula-
tion caused by malaria infection contributes to frequent reactivation of KSHV from latency.
Since KSHV is transmitted by salivary exchange [3, 62, 63], studies examining parasite co-
infections and KSHV viral load in saliva are warranted.
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